Ulla Hald Buhl
Chief Operating Officer at CHOSA ONCOLOGY AB
Network origin in Ulla Hald Buhl first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Extinct | Pharmaceuticals: Major | 15 | |
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark.
10
| Private Company | Pharmaceuticals: Major | 10 |
| Public Company | Pharmaceuticals: Major | 9 | |
| Public Company | Pharmaceuticals: Other | 7 | |
| Public Company | Miscellaneous Commercial Services | 6 | |
Allarity Therapeutics Europe ApS
 Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Oncology Venture US, Inc.
 Oncology Venture US, Inc. Miscellaneous Commercial ServicesCommercial Services Oncology Venture US, Inc. develops therapies for cancer treatment. The company is headquartered in Cambridge, MA.
3
| Subsidiary | Miscellaneous Commercial Services | 3 |
Buhl Krone Holding ApS
1
| Subsidiary | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Ulla Hald Buhl via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ENZON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
Gyros AB
 Gyros AB Medical SpecialtiesHealth Technology Gyros AB engages in the utilization of microfluidic technologies to miniaturize and automate immunoassays. Its Gyrolab xP miniaturizes, integrates, and automates analysis of samples in parallel. The firm's technology delivers immunoassay data through automated control of centrifugal and capillary forces to steer liquid flow in proprietary nanoliter-scale microfluidic structures.The company offers Gyrolab microlaboratory, in the form of a compact disk, can process samples at nanoliter scale, controlled by Gyrolab Workstation. Gyros was founded in 2000 and is headquartered in Uppsala, Sweden. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
| GENMAB A/S | Pharmaceuticals: Major | Chairman Director/Board Member | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Odlander, Fredrikson & Co. AB
 Odlander, Fredrikson & Co. AB Financial ConglomeratesFinance Odlander Fredrikson & Co. AB provides financial support services. The company was founded in 1996 and is headquartered in Stockholm, Sweden. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal | |
| ALK-ABELLÓ A/S | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal | |
| Karolinska Institutet | College/University | Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Director/Board Member | |
| Copenhagen Business School | College/University | Undergraduate Degree Graduate Degree Graduate Degree Graduate Degree Masters Business Admin Graduate Degree Graduate Degree | |
| University of Uppsala | College/University | Masters Business Admin Graduate Degree Doctorate Degree | |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| University of Aarhus | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
TopoTarget UK Ltd.
 TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom. | Drugstore Chains | Chairman Director/Board Member | |
| University of Lund | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| University of Copenhagen | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Medical/Nursing Services | Corporate Officer/Principal Corporate Officer/Principal | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Founder Director/Board Member Founder Chief Executive Officer | |
| Healthcap III Sidefund GP AB | Investment Managers | Director/Board Member Director/Board Member | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| EVOLVA HOLDING SA | Food: Specialty/Candy | Director/Board Member Founder | |
| CANTARGIA AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
Forskarpatent i Syd AB
 Forskarpatent i Syd AB Miscellaneous Commercial ServicesCommercial Services Forskarpatent i Syd AB specialises in the commercialisation, through licensing or new venture spinouts, of patentable inventions emanating mainly from Swedish universities. It holds a portfolio of projects in the format of shares in spinouts, partnered (licensed) and still unpartnered assets. It is involves in projects in pharmaceutical, technology, and food categories. The firm is categorized under patent agency operations. The company was founded on January 18, 1996 and is headquartered in Lund, Sweden. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Chairman Director/Board Member | |
Rigshospitalet
 Rigshospitalet Hospital/Nursing ManagementHealth Services Rigshospitalet is a highly specialized hospital in Denmark that ensures all patients in Denmark have a treatment offer, no matter how rare or complicated their illness is. The hospital is located on Blegdamsvej and in Glostrup. Rigshospitalet prioritizes research and achieves and disseminates results through extensive national and international cooperation. The hospital has subsidiaries in Denmark. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Director of Finance/CFO | |
| Medical Prognosis Institute, Inc. | Chairman Director/Board Member Chief Executive Officer | ||
| SANA AB | Biotechnology | Founder Chief Executive Officer | |
| IDOGEN AB (PUBL) | Biotechnology | Founder Chief Tech/Sci/R&D Officer | |
| HERANTIS PHARMA OYJ | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
| REDWOOD PHARMA AB | Pharmaceuticals: Major | Director/Board Member Chairman | |
| PHARMIVA AB (PUBL) | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
| INITIATOR PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Chairman Founder | |
| SCANDION ONCOLOGY A/S | Pharmaceuticals: Major | Director/Board Member Founder Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| ALLARITY THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Chief Executive Officer Chief Executive Officer | |
| BIOSERGEN AB | Biotechnology | Director/Board Member Director of Finance/CFO | |
Chosa ApS
 Chosa ApS Miscellaneous Commercial ServicesCommercial Services Chosa ApS is a Danish company that provides biotechnology services. The private company is based in Copenhagen, Denmark. The CEOs are Claus Frisenberg Pedersen and Neil Goldsmith. The company was founded in 2022. | Miscellaneous Commercial Services | Chief Executive Officer Chief Executive Officer |
Statistics
International
| Denmark | 23 |
| Sweden | 19 |
| United States | 7 |
| France | 2 |
| United Kingdom | 2 |
Sectoral
| Health Technology | 31 |
| Finance | 7 |
| Consumer Services | 7 |
| Commercial Services | 4 |
| Health Services | 3 |
Operational
| Director/Board Member | 307 |
| Corporate Officer/Principal | 136 |
| Chairman | 111 |
| Chief Executive Officer | 72 |
| Independent Dir/Board Member | 63 |
Most connected contacts
- Stock Market
- Insiders
- Ulla Hald Buhl
- Company connections
